After six rare cases of blood clots, the Centers for Disease Control (CDC) has called on states to temporarily suspend Johnson & Johnson vaccinations. However, medical experts say that the chance of getting a blood clot from Wuhan pneumonia (novel coronavirus disease, COVID-19) is much higher than getting vaccinated, and that the benefits of vaccination still outweigh the drawbacks.
Purvi Parikh, a leading immunologist and allergist in New York, told CNBC, citing relevant data, that compared to the 6.8 million people vaccinated in the United States, only 6 women had blood clots, 1 in 20 people hospitalized with Wuhan lung infection had blood clots, and 1 in 100 people with mild infection had a 1 in 100 chance.
Parikh explained that the CDC is not canceling the emergency use approval of Johnson & Johnson vaccine, and that it is quite common to suspend vaccination to ensure the safety of the public, especially when the number of vaccinations far exceeds the experimental data. She supported the practice of the U.S. regulatory authorities, but called on the public to think more macroscopically about vaccination, and stressed that in the current situation, the benefits of vaccination still outweigh the disadvantages.
In Europe, there were cases of blood clots among AstraZeneca (AZ) vaccine recipients early last month, with more patients being young women, and many countries once suspended vaccination for their nationals and then restricted the age of the recipients.
Both Johnson & Johnson and AZ vaccines are new “viral vector vaccine” (viral vector vaccine). Scientists are studying the relationship between this vaccine-making technology and blood clots.
Recent Comments